SCHEMBL23850702

SCHEMBL23850702

Nc1cc(-c2nnco2)ccc1N1CCCCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 6/20 0.61
S100B P04271 1/20 0.49
KDM4E B2RXH2 4/20 0.47
ALDH1A1 P00352 4/20 0.47
GAA P10253 4/20 0.47
HTT P42858 2/20 0.47
LMNA P02545 2/20 0.47
HSD17B10 Q99714 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.43
POLB P06746 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
RAB9A P51151 1/20 0.42
KEAP1 Q14145 1/20 0.41
TDP2 O95551 1/20 0.41
MAPT P10636 1/20 0.41
THRB P10828 1/20 0.41
CASP3 P42574 1/20 0.41
RECQL P46063 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31587907 1.00 NOTUM (0.61) NOTUMS100BKDM4EALDH1A1GAA
SCHEMBL23850824 0.78 MAPT (0.66) NOTUMALDH1A1GAALMNAL3MBTL1
SCHEMBL23850847 0.78 S100B (0.49) NOTUMS100BKDM4EALDH1A1GAA
SCHEMBL31587612 0.77 RAB9A (0.65) S100BKDM4EALDH1A1GAAHTT
SCHEMBL23850484 0.77 RAB9A (0.65) S100BKDM4EALDH1A1GAAHTT
SCHEMBL21776815 0.76 NOTUM (1.00) NOTUMKDM4ELMNAHSD17B10MEN1
SCHEMBL11652205 0.75 NOTUM (0.53) NOTUMKDM4EALDH1A1LMNAMEN1
SCHEMBL11965639 0.72 NOTUM (0.59) NOTUMKDM4EALDH1A1HTTLMNA
SCHEMBL23850971 0.72 S100B (0.49) S100BKDM4EALDH1A1GAAHTT
SCHEMBL22556283 0.71 NOTUM (0.60) NOTUMKDM4EALDH1A1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12485169-B2 Compounds Grey Wolf Therapeutics Limited (GB) 2025-12-02 US disclosed
US-20230064417-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2023-03-02 US disclosed
EP-3883650-A1 COMPOUNDS Grey Wolf Therapeutics Limited (GB) 2021-09-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230064417-A1 COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRH4, CBR3 NOTUM 3603/4885S100B 2836/4885KDM4E 2853/4885
US-12485169-B2 Compounds SLC10A1, VHL, CFTR NOTUM 2494/4885S100B 2774/4885KDM4E 4372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.